Homology Medicines Announces Upcoming Oral Presentation on pheNIX Gene Therapy Clinical Trial for Adults with PKU
November 05, 2020 09:15 ET
|
Homology Medicines, Inc.
Homology Webcast / Conference Call Scheduled for Friday, November 6 at 4:30 p.m. ET BEDFORD, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines...
Homology Medicines Unveils New In Vivo Gene Therapy Development Program for Hunter Syndrome
October 22, 2020 08:30 ET
|
Homology Medicines, Inc.
HMI-203 Leverages Ability to Cross Blood-Brain-Barrier Following I.V. Administration, and Preclinical Data Showed Improvements in Key Disease Biomarkers Program Expands Homology’s CNS Portfolio ...
Homology Medicines to Participate in Upcoming Conferences
September 18, 2020 09:00 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today participation and presentations at the following virtual...
Homology Medicines Reports Second Quarter 2020 Financial Results and Provides Business Update
August 10, 2020 16:05 ET
|
Homology Medicines, Inc.
Three Cohorts Enrolled in Phase 1/2 pheNIX Gene Therapy Trial for PKU Progressed Into Later Stages of IND-Enabling Studies for MLD Gene Therapy and PKU Gene Editing Programs and Published Key Data ...
Homology Medicines Appoints Jeff Poulton to the Board of Directors
July 21, 2020 08:00 ET
|
Homology Medicines, Inc.
- Executive with Extensive Rare Disease Expertise in Global Finance and Commercial Operations - BEDFORD, Mass., July 21, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic...
Homology Medicines Announces Peer-Reviewed Publication Describing Molecular Characterization of Precise In Vivo Nuclease-Free Gene Editing with PKU Program
May 26, 2020 14:10 ET
|
Homology Medicines, Inc.
- Methods Showed Efficient On-Target Gene Integration with No Unintended DNA Modifications - BEDFORD, Mass., May 26, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic...
Homology Medicines Announces Presentations on its In Vivo Gene Therapy and Gene Editing Programs and Commercial Manufacturing Platform at the American Society of Gene & Cell Therapy Annual Meeting
May 12, 2020 08:00 ET
|
Homology Medicines, Inc.
- Molecular Methods Quantified Precision and Efficiency of Nuclease-Free Gene Editing for PKU - - Manufacturing Enhancements Led to Improved Productivity, Quality and Scalability of Commercial...
Homology Medicines Reports First Quarter 2020 Financial Results and Recent Highlights
May 07, 2020 16:05 ET
|
Homology Medicines, Inc.
- Progressed the pheNIX Trial for PKU and Added Clinical Sites, Completed Clinical Supply for Phase 1/2 and Began Manufacturing Pivotal Supply - - Executed Commercial Manufacturing Process at...
Homology Medicines Announces Presentations at Upcoming American Society for Gene & Cell Therapy Annual Meeting
April 29, 2020 08:00 ET
|
Homology Medicines, Inc.
BEDFORD, Mass., April 29, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic medicines company, announced today upcoming presentations demonstrating the broad applicability...
Homology Medicines Announces Peer-Reviewed Publication of HMI-102 Investigational Gene Therapy Demonstrating Restoration of Normal Metabolic Pathway in PKU Disease Model
March 16, 2020 09:00 ET
|
Homology Medicines, Inc.
- Data Package Supported Initiation of Ongoing pheNIX Clinical Trial for Adults with PKU - BEDFORD, Mass., March 16, 2020 (GLOBE NEWSWIRE) -- Homology Medicines, Inc. (Nasdaq: FIXX), a genetic...